跳到正文
BioPharm International·· 17 天前AI 评分57

FDA 发布个体化人类基因组编辑产品 BLA 申报与上市后管理指南草案

FAQ: What FDA’s Individualized Gene Editing Draft Guidance Means for Developers

AI 导读

FDA 生物制品评价与研究中心(CBER)于 2026 年 10 月 27 日发布《个体化人类基因组编辑产品:BLA 申报与上市后管理考量》草案,拟允许申办方在单一 BLA 中纳入同一基因组编辑产品的多个患者特异变异。草案描述申办方如何界定产品变异边界,并以体外数据支持获批后新增变异。征求意见截止日期为 2026 年 11 月 27 日,文章同时列出草案尚未明确的问题。

正文 · 原文

News|Articles|November 5, 2026

FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.

The US Food and Drug Administration (FDA) has proposed a regulatory framework that would allow sponsors to include multiple patient-specific variants of a genome editing (GE) product in a single biologics license application (BLA). Issued by the Center for Biologics Evaluation and Research (CBER) on October 27, 2026, the draft guidance, Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management, describes how sponsors could establish boundaries for product variation and use in vitro evidence to support additional variants after approval. Comments are due November 27, 2026.¹⁻³

Related to this article

3D rendered medical illustration of male anatomy showing the liver. | Image Credit: © Sebastian Kaulitzki - © Sebastian Kaulitzki - stock.adobe.com

November 5th, 2026

Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.

Read more

Sad blue-grey eyes of elderly woman looking to the side, extreme close-up shot | Image credit: © pressmaster - © pressmaster - stock.adobe.com

November 5th, 2026

VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.

Read more

FDA headquarters at White Oak Campus in Silver Spring, Maryland, USA - January 13, 2020. The United States Food and Drug Administration (FDA) is a federal agency. | Image credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com

November 3rd, 2026

Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.

Read more

Grid of black-and-white brain CT scans with a blue tint, showing cross-sections of the head from the top, front, and side. | Image Credit: © photoprofi30 - stock.adobe.com

November 2nd, 2026

FDA set a May 1, 2027 target date for AMT-130, a one-time gene therapy that silences the huntingtin gene, and plans an advisory committee meeting.

Read more

Human Respiratory System Lungs Anatomy | Image credit: © magicmine - © magicmine - stock.adobe.com

November 2nd, 2026

Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.

Read more

3D illustration of a translucent blue human torso with the small and large intestines highlighted, the lower colon and rectum glowing red. | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 5th, 2026

Healthy-volunteer data show sustained TL1A suppression and a profile supporting infrequent subcutaneous dosing. Caldera also licensed a second bispecific, targeting IL-17 and TL1A, from Qyuns Therapeutics.

Read more

Hand inserts a molecule into DNA. | Image credit: © natali_mis - © natali_mis - stock.adobe.com

November 4th, 2026

Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.

Read more

Close-up of an older person’s hands with several finger joints highlighted in red, against a white background. | Image Credit: © doucefleur - stock.adobe.com

November 4th, 2026

The half-life-extended antibody failed its primary endpoints in two Phase 2 SKYWAY sub-studies, so Spyre is dropping it in rheumatic diseases and moving it into a combination trial in hidradenitis suppurativa.

Read more

来源:BioPharm International · biopharminternational.com

所属事件

查看事件全部
FDA发布个体化基因编辑产品BLA指南草案并征求意见